Ignite Creation Date:
2025-12-24 @ 9:49 PM
Ignite Modification Date:
2026-01-01 @ 8:27 PM
Study NCT ID:
NCT03805932
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-07-24
First Post:
2019-01-15
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-10-03
Start Date Type:
ACTUAL
Primary Completion Date:
2023-07-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2019-01-15
First Submit QC Date:
None
Study First Post Date:
2019-01-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-11-10
Results First Submit QC Date:
None
Results First Post Date:
2023-11-28
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-14
Last Update Post Date:
2025-07-24
Last Update Post Date Type:
ACTUAL